GZQA-TRANSCEND-T2D-3 Study
Enrollment is open
Study Overview
The study is evaluating the safely and efficacy of an investigational medicine for adult with type 2 diabetes and chronic kidney disease. If you are eligible and decide to take part in the study you will be randomly assigned to 1 of 4 groups. Three of these groups will take the investigational medicine but contains no active ingredients. Each of the 3 groups taking the investigational medicine will be assigned a different dose.
You will take your study medicine (investigational or placebo) as an injection once weekly for 52 weekly. During the study, you will attend in-person visits with doctors and researchers at the study center.
-
You may be able to participate if you:
Are aged 18 or over
Have type 2 diabetes and moderate or severe chronic kidney disease
Have been unable to control your blood sugar with insulin glaring or similar medications with or without metformin and/or sodium-glucose inhibitors
Have a BMI of 23kg/m^2 or greater.
Please note that this list is not extensive. If you are interested in participating, a staff member will review additional eligibility criteria with you and answer any questions you may have.
-
If you are eligible and decide to take part in the TRANSCEND-T2D-3 Study, you will be randomly assigned to 1 of 4 groups. Three of these groups will take the investigational medicine. The remaining group will take a placebo, which looks like the investigational medicine but contains no active ingredients. Each of the 3 groups taking the investigational medicine will be assigned a different dose.
You will take your study medicine (investigational or placebo) as an injection once weekly for 52 weeks. During the study, you will attend in-person visits with doctors and researchers at the study center.